Abstract: The present invention relates to novel polypeptides having a skin whitening activity and use thereof. More particularly, the present invention relates to an isolated polypeptide consisting (essentially) of any one amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, and SEQ ID NO: 7, a skin whitening cosmetic composition comprising the polypeptide as an active ingredient, or a pharmaceutical composition for preventing or treating a pigmentation disease.

Abstract: The present invention relates to an antibody specifically binding to a tryptophanyl-tRNA synthetase (WRS) protein and, more specifically, to: an antibody, or a fragment of the antibody, specifically binding to a polypeptide of an amino acid sequence represented by SEQ ID NO: 2 in a WRS protein; a polynucleotide encoding the antibody and a vector comprising same; a cell transformed using same; and a use thereof.

Abstract: The present invention relates to an antibody specifically binding to a WRS (tryptophanyl-tRNA synthetase) protein, and a use thereof. More specifically, the present invention pertains to an antibody specifically binding to a polypeptide of an amino acid sequence represented by SEQ ID NO:2 in the WRS (tryptophanyl-tRNA synthetase) protein, or a fragment of the antibody, a polynucleotide encoding the antibody, a vector comprising the polynucleotide, a cell transformed using the vector, and a use of the cell.

Abstract: In one example embodiment, a method performed under control of a wearable video playing device includes: transmitting identifying information for a location of the wearable video playing device to a video content provider; receiving, from the video content provider, video content information regarding a plurality of video contents recorded near the location; displaying, on a user interface, at least one video content identifier respectively corresponding to the video contents, wherein the at least one video content identifier is associated with the location; receiving an input to select one of the at least one video content identifier; and playing video content, from among the plurality of video contents recorded near the location, corresponding to the selected video content identifier.

Abstract: The disclosure is related to providing a machine to machine (M2M0 service. A user interface (UI) template associated with a M2M device may be retrieved when a message is received from the M2M device. Then, data collected from the M2M device may be combined with the retrieved UI template. The M2M service associated with the M2M device may be provided by embedding the combined data to application data for producing a M2M service user interface (UI) of the associated M2M service.

Abstract: The present invention provides a method for separating and preparing a therapeutic agent for chronic myelogenous leukimeia capable of effectively inhibiting growth of T315I, which is known as a mutation of a BCR-ABL fusion gene that causes chronic myelogenous leukemia, comprising the steps of: 1) preliminary extracting by adding ethyl acetate to finely chopped bark of Liriodendron tulipifera L., adding butanol to an extracted fluid for layer-separating an ethyl acetate layer and a butanol layer, removing the butanol layer, and decompression-condensing the remainder to obtain a crude extract; and 2) adding a C1-C3 lower alcohol aqueous solution and n-hexane to the obtained crude extract, removing lipids and water insoluble material dissolved in the n-hexane layer, and obtaining and separating a lower alcohol aqueous solution layer to separate and refine highly pure epi-tulipinolide and costunolide.

Abstract: The present invention relates to a pharmaceutical composition containing, as an active ingredient, a Liriodendron tulipifera L. bark extract for treating chronic myelogneous leukemia. More specifically, the present invention relates to the pharmaceutical composition, containing, as the active ingredient, the Liriodendron tulipifera L. bark extract useful in selectively inhibiting mutant enzyme T315I from a mutation of a BCR-ABL fusion gene that causes chronic myelogenous leukemia, and to a use of epi-Tulipinolide which is an active ingredient of the composition.

Abstract: In one example embodiment, a method performed under control of a wearable video playing device includes: transmitting identifying information for a location of the wearable video playing device to a video content provider; receiving, from the video content provider, video content information regarding a plurality of video contents recorded near the location; displaying, on a user interface, at least one video content identifier respectively corresponding to the video contents, wherein the at least one video content identifier is associated with the location; receiving an input to select one of the at least one video content identifier; and playing video content, from among the plurality of video contents recorded near the location, corresponding to the selected video content identifier.

Abstract: A molecular glass compound comprises a vinyl ether adduct of an aromatic vinyl ether of formula C(R1)2?C(R2)—O-(L)n-Ar1, and a calix[4]arene, wherein R1 and R2 are each independently a single bond, H, C1-20 alkyl, C1-20 haloalkyl, C6-20 aryl, C6-20 haloaryl, C7-20 aralkyl, or C7-20 haloaralkyl, L is a C1-20 linking group, n is 0 or 1, and Ar1 is a halo-containing monocyclic, or substituted or unsubstituted polycyclic or fused polycyclic C6-20 aromatic-containing moiety, wherein R1 and R2 are connected to Ar1 when either or both of R1 and R2 is a single bond and n is 0. A photoresist, comprising the molecular glass compound, a solvent, and a photoacid generator, a coated substrate, comprising (a) a substrate having one or more layers to be patterned on a surface thereof; and (b) a layer of a photoresist composition over the one or more layers to be patterned, and a method of forming the molecular glass compound, are also disclosed.

Abstract: A copolymer has formula: wherein R1-R5 are independently H, C1-6 alkyl, or C4-6 aryl, R6 is a fluorinated or non-fluorinated C5-30 acid decomposable group; each Ar is a monocyclic, polycyclic, or fused polycyclic C6-20 aryl group; each R7 and R8 is —OR11 or —C(CF3)2OR11 where each R11 is H, a fluorinated or non-fluorinated C5-30 acid decomposable group, or a combination; each R9 is independently F, a C1-10 alkyl, C1-10 fluoroalkyl, C1-10 alkoxy, or a C1-10 fluoroalkoxy group; R10 is a cation-bound C10-40 photoacid generator-containing group, mole fractions a, b, and d are 0 to 0.80, c is 0.01 to 0.80, e is 0 to 0.50 provided where a, b, and d are 0, e is greater than 0, the sum a+b+c+d+e is 1, l and m are integers of 1 to 4, and n is an integer of 0 to 5. A photoresist and coated substrate, each include the copolymer.

Abstract: A copolymer has formula: wherein R1-R5 are independently H, C1-6 alkyl, or C4-6 aryl, R6 is a fluorinated or non-fluorinated C5-30 acid decomposable group; each Ar is a monocyclic, polycyclic, or fused polycyclic C6-20 aryl group; each R7 and R8 is —OR11 or —C(CF3)2OR11 where each R11 is H, a fluorinated or non-fluorinated C5-30 acid decomposable group, or a combination; each R9 is independently F, a C1-10 alkyl, C1-10 fluoroalkyl, C1-10 alkoxy, or a C1-10 fluoroalkoxy group; R10 is a cation-bound C10-40 photoacid generator-containing group, mole fractions a, b, and d are 0 to 0.80, c is 0.01 to 0.80, e is 0 to 0.50 provided where a, b, and d are 0, e is greater than 0, the sum a+b+c+d+e is 1, l and m are integers of 1 to 4, and n is an integer of 0 to 5. A photoresist and coated substrate, each include the copolymer.

Abstract: Antimicrobial and anticancer peptides engineered using Gaegurin 5 isolated from Korean frog (Rana rugosa), which have a smaller structure compared with previously known Gaegurin peptides and show potent antimicrobial and anticancer activity. Specifically, the antimicrobial and anticancer peptides synthesized from the shortest length of Gaegurin 5, show potent antimicrobial activity against gram positive and negative strains, good safety with very low hemolytic activity and favorable advantages such as drug absorption and drug transportation due to its advantageous structural property, which can be useful as a potent antimicrobial or anticancer agent.

Abstract: The present invention is related to antimicrobial and anticancer peptide engineering using Gaegurin 5 isolated from Korean frog (Rana rugosa), which have smaller structure compared with previously known Gaegurin peptide and shows potent antimicrobial and anticancer activity. Specifically, the antimicrobial and anticancer peptide of the present invention synthesized from the shortest length of Gaegurin 5, show potent antimicrobial activity against gram positive and negative strains, good safety with very low hemolytic activity and favorable advantages such as drug absorption and drug transportation due to its advantageous structural property, which can be useful as a potent antimicrobial or anticancer agent.